How the FDA approval status of your peptide products affects your insurance needs and what carriers look for when underwriting your risk.
Dean Hamid, CLCS, AINS
PRIA Brokers — Peptide Insurance Specialist
Not all peptides are treated equally by insurance carriers — and the single most important variable is FDA approval status. Whether a peptide is FDA-approved, on the FDA's shortage list, a compounded version of an approved drug, or a research chemical with no approval pathway at all changes everything about how carriers assess and price the risk.
Understanding this distinction is essential for any business operating in the peptide space.
FDA-approved peptide medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and others — have undergone rigorous clinical testing and carry the full weight of FDA regulatory oversight. From an insurance standpoint, this creates a mixed picture:
Advantages for insurance:
Established safety and efficacy data reduces product liability uncertainty
Clear prescribing guidelines limit professional liability exposure
Carriers have more underwriting data on adverse event rates
Challenges for insurance:
Products dispensed outside their labeled indications (off-label prescribing) can void some coverage provisions
Compounded versions of FDA-approved drugs (even during shortage periods) are treated differently than the FDA-approved originator product
Litigation exposure is high because the product is widely used and plaintiffs' attorneys have established playbooks
The gray zone that has dominated the insurance conversation since 2021 is compounded semaglutide and tirzepatide — products formulated by 503A pharmacies and 503B outsourcing facilities to meet demand when the branded drugs were on the FDA shortage list.
The FDA's position has evolved: as shortages were resolved, the FDA moved to restrict compounding of these specific molecules. Many compounders now operate under uncertainty about whether their current practices are compliant.
From an insurance perspective, compounded versions of FDA-approved drugs are underwritten differently than the branded product:
Higher product liability premiums — compounders bear the full burden of product quality, whereas manufacturers of FDA-approved drugs share liability with the broader pharmaceutical supply chain
Regulatory defense exposure — the FDA has actively issued warning letters and pursued enforcement against compounders of GLP-1 medications
Carrier exclusions — some carriers are now explicitly excluding compounded semaglutide and tirzepatide from standard pharmacy policies
PRIA Brokers works with specialty carriers who maintain coverage for compliant compounding operations, but the underwriting process is more intensive than it was two years ago.
The category that creates the most insurance challenges is research peptides — BPC-157, TB-500, CJC-1295, ipamorelin, PT-141, and dozens of others. These molecules are not FDA-approved for human use. They are legally sold as research chemicals, but in practice many are used by humans for performance enhancement, recovery, or anti-aging purposes.
Insurance implications for research peptide businesses:
Very limited carrier market — most standard carriers will not underwrite product liability for human use of research chemicals
Significant coverage carve-outs — policies for research chemical companies typically exclude claims arising from human consumption or injection
Higher premiums when coverage is available — the combination of limited data, human use risk, and regulatory uncertainty makes this a challenging class
The key distinction carriers make: is the product being sold and used strictly as a research chemical, or is there a reasonable expectation of human use? Companies that market research peptides with implied human use claims — testimonials, dosing guides for humans, before/after photos — face the most difficult underwriting environment.
When assessing a peptide business's insurance application, underwriters evaluate:
1. Product portfolio composition — the ratio of FDA-approved products to compounded drugs to research chemicals
2. Sales channel — consumer-direct sales to humans vs. sales to licensed researchers or healthcare providers
3. Regulatory compliance posture — current or past FDA/DEA enforcement actions, warning letters, or consent decrees
4. Quality systems — cGMP certifications, third-party testing, batch records, and adverse event reporting
5. Claims history — prior product liability claims or FDA enforcement actions are significant underwriting red flags
Businesses operating across multiple product categories — for example, a distributor that sells both compounded GLP-1 products and research peptides — face a particularly complex underwriting environment. Carriers may:
Write coverage for some products but exclude others
Require separate policies for different product lines
Impose higher deductibles on higher-risk product categories
PRIA Brokers specializes in constructing layered coverage programs for multi-product peptide businesses, ensuring that each product category is properly addressed rather than leaving dangerous gaps.
Understanding how your product mix affects your insurability is the starting point for building an adequate coverage program. PRIA Brokers offers a no-obligation coverage assessment for peptide businesses at any stage — from startup to established distributor.
Contact us at (888) 998-7742 or dhamid@priabrokers.com to schedule a review.
Partner Resource
Want to go deeper on peptide science?
The Peptide University covers compound profiles, protocols, and research — the essential complement to understanding your insurance needs.
PRIA Brokers specializes in coverage for peptide manufacturers, GLP-1 compounders, distributors, and suppliers. Compare quotes from A-rated specialty carriers.